The GLP-1 drug market in India is rapidly shifting. Previously a high-margin area, it is now becoming more common as patents expire. The focus has moved from exclusive drug rights to gaining market share through volume and competitive pricing.
Price Pressure Mounts as Semaglutide Patent Expires
India's GLP-1 drug market is undergoing a major change following the expiry of the Semaglutide patent on March 20, 2026. The market is expected to grow significantly, potentially reaching ₹5,000 crore by 2030, a fivefold increase from an estimated ₹1,000-1,200 crore in 2025. However, this growth is tied to sharp price drops. Drug prices are forecast to fall by 40% to 50% in FY27, and by another 10% to 30% in FY28 as more generic versions enter. This intense price competition is already reshaping the market, with companies like Torrent Pharmaceuticals and Dr. Reddy's Laboratories releasing generic Semaglutide near the patent expiry. The global GLP-1 market is also set for substantial growth, projected to exceed $200 billion by 2030, highlighting the vast opportunity and fierce competition. Stock prices on March 27, 2026, showed how the market views these companies: Sun Pharmaceutical Industries closed near ₹1,793.60, Dr. Reddy's Laboratories at about ₹1,282.0, and Emcure Pharmaceuticals around ₹1,595.50.
Companies Choose Unique Paths in Competitive Market
As the market opens to generics, companies are pursuing different strategies to gain market share. Sun Pharmaceutical Industries, India's largest drug maker, is targeting the mass market with its generic Semaglutide brands, Noveltreat and Sematrinity. These offer weekly therapy at costs between ₹750 and ₹2,000, significantly undercutting premium choices. This focus on affordability is crucial for reaching a price-sensitive market. Dr. Reddy's Laboratories, meanwhile, has launched Obeda, a premium generic priced at ₹4,200 per month. It uses its own technology and aims for a wide global release in over 80 countries, banking on quality and global reach. Emcure Pharmaceuticals has an exclusive partnership with Novo Nordisk for its innovator drug, Poviztra, priced at ₹8,790 per month. Emcure plans to use its large cardiovascular sales team and the drug's established data to stay competitive. Valuation figures show Sun Pharma trading at a P/E ratio of about 34-39, Dr. Reddy's at around 18-19, and Emcure between 33-36. The industry's average P/E is about 26.5, meaning Sun Pharma and Emcure are priced higher than the sector average, while Dr. Reddy's is closer to or below it.
Analysts Divided Amidst Sector Challenges
Analyst opinions are splitting sharply, driven by worries over the GLP-1 market becoming more common and companies depending too much on one type of product. UBS has downgraded Dr. Reddy's Laboratories, Lupin, and Zydus Lifesciences to 'Sell' ratings. They cited these companies' strong reliance on generic GLP-1 sales and a shortage of other growth areas. However, UBS rates Sun Pharma as 'Buy,' acknowledging its innovation and varied strategy. Jefferies is cautious on Dr. Reddy's with an 'Underperform' rating but recommends 'Buy' for Emcure Pharmaceuticals. The Indian pharmaceutical sector overall is expected to grow by 7-9% in FY26, facing continued regulatory checks and global economic changes, although demand within India provides a strong foundation. Market capitalizations differ: Sun Pharma is valued at about ₹4.3 Trillion, Dr. Reddy's at roughly ₹1.05 Trillion, and Emcure Pharmaceuticals at approximately ₹31,350 Crore.
Risks Emerge in the Price-Focused Market
The rapid influx of generic GLP-1 drugs creates significant risks for all companies involved. Sun Pharma's strategy of affordable pricing, while boosting sales volume, could lead to much lower profit margins. Dr. Reddy's approach of premium pricing faces hurdles in gaining acceptance in India against cheaper rivals, alongside challenges in executing its large-scale global expansion. Producing Obeda in-house demands ongoing investment and operational efficiency. Emcure's partnership with Novo Nordisk for its innovator drug provides early access but links Emcure's success to its partner's future decisions and pricing power, as well as the risk of this drug also becoming common. Moreover, getting generic drugs approved in India, overseen by the CDSCO and DCGI, requires strict bioequivalence tests and adherence to rules, increasing time and cost for new entrants. The intense competition itself is a major risk.
Outlook: Growth Potential Amid Competition
Even with falling prices, the opportunity in GLP-1 drugs remains significant. Analysts predict the Indian Semaglutide market could reach $1-2 billion by 2030. The Indian pharmaceutical industry overall is expected to see double-digit growth in FY26-27, fueled by domestic demand and growing exports. Brokerage firms ICICI Securities and JM Financial rate Sun Pharma as 'Buy,' with price targets of ₹1,895 and ₹2,115, respectively, signaling confidence in its varied products and research. However, worries about too much reliance on GLP-1 drugs have resulted in 'Sell' ratings for some rivals from analysts like UBS, showing how the sector is split by strategic execution and the breadth of company portfolios.